<DOC>
	<DOCNO>NCT00070707</DOCNO>
	<brief_summary>An association seasonal allergic rhinitis ( SAR ) allergic asthma establish epidemiologic , pathophysiologic , therapeutic study . This study compare Nasonex Nasal Spray Placebo treat nasal asthma symptom experience subject SAR concomitant asthma .</brief_summary>
	<brief_title>Efficacy Safety Nasonex v . Placebo Subjects With SAR Concomitant Asthma ( Study P03280 )</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<mesh_term>Mometasone Furoate</mesh_term>
	<criteria>Eligibility Criteria : Subject must least twoyear history seasonal allergic rhinitis increase asthma symptom associate allergy season study . FEV 1 70 % predict Screening Baseline visit . Subject must demonstrate increase absolute FEV 1 less 12 % , absolute volume increase least 200 ml , reversibility test Screening within past 12 month . Subjects must skin test positive ( skin prick test wheal diameter least 3mm large diluent control intradermal test wheal diameter least 7 mm large diluent control ) screening , within 12 month prior screen visit , seasonal allergen ( may include seasonal mold ) prevalent study period . Subjects asthma require chronic use inhale systemic corticosteroid . Subjects morbidly obese ( BMI &gt; 35 )</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Seasonal Allergic Rhinitis</keyword>
	<keyword>Concomitant Asthma</keyword>
</DOC>